Recently, the TRED-HF trial exclusively evaluated DCM patients and reported that approximately half of patients in the medication discontinuation group eventually had a substantial decline in LV systolic function, a rise in LV end-diastolic volume or NT-proBNP level, or clinical deterioration25. Here, NPPB is linked to familial dilated cardiomyopathy.